Rocket Pharmaceuticals (RCKT) EBT (2014 - 2026)

Rocket Pharmaceuticals has disclosed EBT across 13 years of filings, most recently posting -$48.8 million for Q1 2026.

• EBT for Q1 2026 came in at -$48.8 million, up 23.14% year-over-year; the trailing twelve-month figure through Mar 2026 was -$215.7 million (up 18.76% YoY), and the FY2025 annual result was -$230.4 million, up 13.64% from the prior year.
• EBT came in at -$48.8 million for Q1 2026 at Rocket Pharmaceuticals, down from -$43.7 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$42.4 million in Q1 2022 to a low of -$71.9 million in Q2 2024.
• The 5-year median for EBT is -$62.9 million (2023), against an average of -$60.3 million.
• Across the five-year window, EBT tumbled 59.79% in 2022 and gained 28.93% in 2025, its largest moves.
• Rocket Pharmaceuticals' EBT stood at -$68.3 million in 2022, then increased by 7.86% to -$62.9 million in 2023, then increased by 2.2% to -$61.6 million in 2024, then increased by 28.93% to -$43.7 million in 2025, then slipped by 11.61% to -$48.8 million in 2026.
• The last three EBT figures came in at -$48.8 million (Q1 2026), -$43.7 million (Q4 2025), and -$52.0 million (Q3 2025), per Business Quant data.